Evidence map›Paper›PMID 31787100›Full record

ArticleSystematic reviews2019

The association of telomere length with substance use disorders: systematic review and meta-analysis protocol.

Fernando Navarro-Mateu, María Rubio-Aparicio, Pedro Cayuela, Francisco-Javier Álvarez, Agustín Roca-Vega, María Dolores Chirlaque, María Luisa Cayuela, Mathilde Husky, Salvador Martínez, Julio Sánchez-Meca

Open access · goldAbstract read
In one paragraph

Article in Systematic reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Within subject cross-tissue analyzes of epigenetic clocks in substance use disorder postmortem brain and blood.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Fernando Navarro-MateuUnidad de Docencia, Investigación y Formación en Salud Mental (UDIF-SM), Servicio Murciano de Salud, c/ Lorca, n° 58, 30120, Murcia, Spain. fernando.navarro@carm.es.ORCID 0000-0002-3228-623X
María Rubio-AparicioDepartamento Psicología de la Salud, University of Alicante, Alicante, Spain.
Pedro CayuelaEscuela Universitaria de Enfermería de Cartagena, University of Murcia, Murcia, Spain.
Francisco-Javier ÁlvarezUnidad de Docencia, Investigación y Formación en Salud Mental (UDIF-SM), Servicio Murciano de Salud, c/ Lorca, n° 58, 30120, Murcia, Spain.
Agustín Roca-VegaBiblioteca Virtual MurciaSalud, Centro Tecnológico de Información y Documentación Sanitaria, Servicio Murciano de Salud, Murcia, Spain.
María Dolores ChirlaqueCIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
María Luisa CayuelaIMIB-Arrixaca, Murcia, Spain.
Mathilde HuskyLaboratoire de Psychologie EA4139, Université de Bordeaux, Bordeaux, France.
Salvador MartínezInstituto de Neurociencias, UMH-CSIC, Alicante, Spain.
Julio Sánchez-MecaDepartamento de Psicología Básica y Metodología, University of Murcia, Murcia, Spain.
Instituto Murciano de Investigación Biosanitaria · ESServicio Murciano de Salud · ESUniversidad de Murcia · ESInstituto de Neurociencias · ESUniversité de Bordeaux · FRUniversity of Alicante · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe present protocol was designed for a systematic review and meta-analysis aimed at determining the association of telomere length with substance use disorders with the exclusion of nicotine addiction, and to identify potential moderators of the effect of telomere length. Such methodological information may provide guidance to improve the quality of future research on this important topic.

methodsPotential studies will be identified through electronic databases (PubMed/MEDLINE, EMBASE, PsycINFO, and Web of Science) up from inception onwards. The inclusion criteria will include published or unpublished observational studies (cohort, case-control, and cross-sectional studies) reporting telomere length in adult patients with substance use disorder compared with a control group. Non-human studies or other study designs such as reviews, case-only, family-based, and/or population studies with only healthy participants will be excluded, as well as those focused solely on nicotine addiction. The main outcome will be telomere length in adults with substance use disorder (primary) and, specifically, in those with alcohol use disorder (secondary). Two investigators will independently evaluate the preselected studies for possible inclusion and will extract data following a standardized protocol. Disagreements will be resolved by consensus. The risk of bias of all included studies will be assessed using the Newcastle-Ottawa Quality Assessment Scale for non-randomized studies. Data will be converted into standardized mean differences as effect size index, and random-effects models will be used for the meta-analysis. Cochran's Q statistic, I DISCUSSION: This systematic review will assess the association of telomere length with substance use disorders aside from nicotine addiction. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration number CRD42019119785.

Indexed as

Meta-Analysis as TopicResearch DesignSystematic Reviews as TopicTelomere HomeostasisHumansSubstance-Related DisordersMeta-analysisSubstance use disordersSystematic reviewTelomere length

Identifiers

PMID31787100
PMCPMC6886210
OpenAlexW2990944563

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.